Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis

BACKGROUND AND OBJECTIVES: To identify biomarkers associated with treatment response in patients with multiple sclerosis (MS) treated with the oral therapies teriflunomide, dimethyl fumarate (DMF), and fingolimod. METHODS: Serum levels of IL-6, IL-17, TNF-α, granulocyte-macrophage colony-stimulating...

Descripción completa

Detalles Bibliográficos
Autores principales: Fissolo, Nicolás, Pappolla, Agustin, Rio, Jordi, Villar, Luisa M., Perez-Hoyos, Santiago, Sanchez, Alex, Gutierrez, Lucía, Montalban, Xavier, Comabella, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679885/
https://www.ncbi.nlm.nih.gov/pubmed/36411079
http://dx.doi.org/10.1212/NXI.0000000000200050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679885/
https://www.ncbi.nlm.nih.gov/pubmed/36411079
http://dx.doi.org/10.1212/NXI.0000000000200050

Ejemplares similares